Galectin Therapeutics Inc. – NASDAQ:GALT

Galectin Therapeutics stock price today

$3.81
+2.66
+231.3%
Financial Health
0
1
2
3
4
5
6
7
8
9

Galectin Therapeutics stock price monthly change

-48.66%
month

Galectin Therapeutics stock price quarterly change

-48.66%
quarter

Galectin Therapeutics stock price yearly change

-31.14%
year

Galectin Therapeutics key metrics

Market Cap
56.07M
Enterprise value
142.39M
P/E
-3.04
EV/Sales
N/A
EV/EBITDA
-2.50
Price/Sales
N/A
Price/Book
-3.57
PEG ratio
0.12
EPS
-0.67
Revenue
N/A
EBITDA
-37.24M
Income
-41.02M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Galectin Therapeutics stock price history

Galectin Therapeutics stock forecast

Galectin Therapeutics financial statements

Galectin Therapeutics Inc. (NASDAQ:GALT): Profit margin
Jun 2023 0 -9.11M
Sep 2023 0 -10.42M
Dec 2023 80K -9.99M -12496.25%
Mar 2024 0 -11.48M
Galectin Therapeutics Inc. (NASDAQ:GALT): Analyst Estimates
2025 36.32M -95.65M -263.36%
2026 179.68M -58.35M -32.48%
2027 385.24M 79.40M 20.61%
2028 572.21M 206.34M 36.06%
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
Galectin Therapeutics Inc. (NASDAQ:GALT): Payout ratio
Payout ratio 0%
Galectin Therapeutics Inc. (NASDAQ:GALT): Dividend Yield
2019 0.26%
2020 0.11%
2021 0.14%
2022 0.14%
2023
Galectin Therapeutics Inc. (NASDAQ:GALT): Debt to assets
Jun 2023 20081000 71.20M 354.6%
Sep 2023 22163000 73.03M 329.54%
Dec 2023 28200000 88.44M 313.62%
Mar 2024 25890000 96.97M 374.57%
Galectin Therapeutics Inc. (NASDAQ:GALT): Cash Flow
Jun 2023 -9.83M 0 10M
Sep 2023 -7.63M 0 10.03M
Dec 2023 -4.70M 0 10M
Mar 2024 -12.10M 0 10M

Galectin Therapeutics alternative data

Galectin Therapeutics Inc. (NASDAQ:GALT): Employee count
Aug 2023 12
Sep 2023 12
Oct 2023 12
Nov 2023 12
Dec 2023 12
Jan 2024 12
Feb 2024 12
Mar 2024 12
Apr 2024 12
May 2024 28
Jun 2024 28
Jul 2024 14

Galectin Therapeutics other data

12.75% +0.40%
of GALT is owned by hedge funds
7.46M +137.21K
shares is hold by hedge funds

Galectin Therapeutics Inc. (NASDAQ:GALT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 500 0
Apr 2024 4500 25000
Jun 2024 2500 0
Jul 2024 400 0
Aug 2024 3500 0
Oct 2024 11800 0
Dec 2024 33469 109654
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ZORDANI RICHARD A. JR. director
Common Stock 10,000 $0.82 $8,160
Purchase
ELDRED KARY director
Common Stock 13,469 $0.82 $11,045
Purchase
FREEMAN KEVIN D director Common Stock 10,000 $0.81 $8,130
Option
JAMIL KHURRAM officer: Chief Medical Officer
Common Stock 40,000 N/A N/A
Sale
JAMIL KHURRAM officer: Chief Medical Officer
Common Stock 13,654 $0.88 $12,043
Option
JAMIL KHURRAM officer: Chief Medical Officer
Restricted Stock Units 40,000 N/A N/A
Option
LEWIS JOEL director, officer.. Common Stock 56,000 N/A N/A
Sale
LEWIS JOEL director, officer.. Common Stock 56,000 $0.89 $49,616
Option
LEWIS JOEL director, officer.. Restricted Stock Units 56,000 N/A N/A
Option
CALLICUTT JACK W officer: Chief Financial Officer
Common Stock 40,000 N/A N/A
Patent
Application
Filling date: 28 Sep 2020 Issue date: 1 Apr 2021
Application
Filling date: 3 Aug 2020 Issue date: 14 Jan 2021
Grant
Filling date: 30 Jul 2019 Issue date: 13 Oct 2020
Grant
Filling date: 28 Aug 2017 Issue date: 18 Aug 2020
Application
Filling date: 30 Jul 2019 Issue date: 12 Mar 2020
Grant
Filling date: 8 May 2018 Issue date: 24 Sep 2019
Grant
Filling date: 22 Jan 2018 Issue date: 3 Sep 2019
Friday, 20 December 2024
benzinga.com
globenewswire.com
Monday, 9 December 2024
zacks.com
Monday, 18 November 2024
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Tuesday, 15 October 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Tuesday, 13 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Tuesday, 18 June 2024
marketwatch.com
Tuesday, 4 June 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Friday, 5 April 2024
InvestorPlace
Wednesday, 20 March 2024
Seeking Alpha
Monday, 23 October 2023
GlobeNewsWire
Tuesday, 26 September 2023
GlobeNewsWire
Thursday, 14 September 2023
Seeking Alpha
Wednesday, 13 September 2023
GlobeNewsWire
Monday, 11 September 2023
GlobeNewsWire
Thursday, 7 September 2023
GlobeNewsWire
Thursday, 17 August 2023
Zacks Investment Research
Thursday, 18 May 2023
InvestorPlace
Monday, 28 November 2022
GlobeNewsWire
Friday, 14 October 2022
GlobeNewsWire
Thursday, 8 September 2022
GlobeNewsWire
Monday, 11 July 2022
Seeking Alpha
Monday, 23 May 2022
GlobeNewsWire
Thursday, 6 January 2022
GlobeNewsWire
Friday, 5 November 2021
GlobeNewsWire
Tuesday, 5 October 2021
GlobeNewsWire
  • What's the price of Galectin Therapeutics stock today?

    One share of Galectin Therapeutics stock can currently be purchased for approximately $3.81.

  • When is Galectin Therapeutics's next earnings date?

    Unfortunately, Galectin Therapeutics's (GALT) next earnings date is currently unknown.

  • Does Galectin Therapeutics pay dividends?

    No, Galectin Therapeutics does not pay dividends.

  • How much money does Galectin Therapeutics make?

    Galectin Therapeutics has a market capitalization of 56.07M.

  • What is Galectin Therapeutics's stock symbol?

    Galectin Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "GALT".

  • What is Galectin Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Galectin Therapeutics?

    Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Galectin Therapeutics's key executives?

    Galectin Therapeutics's management team includes the following people:

    • Dr. Pol F. Boudes Chief Medical Officer(age: 68, pay: $663,020)
    • Mr. Joel Lewis Pres, Chief Executive Officer & Director(age: 55, pay: $601,100)
  • How many employees does Galectin Therapeutics have?

    As Jul 2024, Galectin Therapeutics employs 14 workers, which is 50% less then previous month and 17% more then previous quarter.

  • When Galectin Therapeutics went public?

    Galectin Therapeutics Inc. is publicly traded company for more then 23 years since IPO on 4 Sep 2002.

  • What is Galectin Therapeutics's official website?

    The official website for Galectin Therapeutics is galectintherapeutics.com.

  • Where are Galectin Therapeutics's headquarters?

    Galectin Therapeutics is headquartered at 4960 Peachtree Industrial Boulevard, Norcross, GA.

  • How can i contact Galectin Therapeutics?

    Galectin Therapeutics's mailing address is 4960 Peachtree Industrial Boulevard, Norcross, GA and company can be reached via phone at +678 6203186.

Galectin Therapeutics company profile:

Galectin Therapeutics Inc.

galectintherapeutics.com
Exchange:

NASDAQ

Full time employees:

14

Industry:

Biotechnology

Sector:

Healthcare

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

4960 Peachtree Industrial Boulevard
Norcross, GA 30071

CIK: 0001133416
ISIN: US3632252025
CUSIP: 363225202